







an Open Access Journal by MDPI

Cell Cycle Deregulation in Cancers

Guest Editor:

Dr. Rebecca S. Hartley

Department of Cell Biology and Physiology, MSC08-4750, University of New Mexico, Albuquerque, NM 87131, USA

Deadline for manuscript submissions:

closed (15 October 2013)

Message from the Guest Editor

Dear Colleagues,

Loss of normal cell cycle control is a hallmark of cancer, resulting in targeting of cell cycle regulators for cancer therapy. In general, strategies used to exploit the deregulated cancer cell cycle by directly targeting cell cycle regulators do not provide cancer specificity. This issue of Cancers invites contributions of original research reports, clinical studies, and review articles that focus on cancer specific modifications that would allow indirect targeting of cell cycle deregulation. Potential topics include modifications of the microenvironment, inflammatory signaling, stress response, and post-transcriptional events that result in cell cycle deregulation.

Dr. Rebecca S. Hartley Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us